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Distributed radiomics as a signature 
validation study using the Personal 
Health train infrastructure
Zhenwei Shi  1,7*, Ivan Zhovannik1,2,7, Alberto Traverso1,6, Frank J. W. M. Dankers1,2, 
Timo M. Deist1,3, Petros Kalendralis1, René Monshouwer2, Johan Bussink2, Rianne Fijten  1, 
Hugo J. W. L. Aerts4,5, Andre Dekker1 & Leonard Wee1
Prediction modelling with radiomics is a rapidly developing research topic that requires access to vast 
amounts of imaging data. Methods that work on decentralized data are urgently needed, because 
of concerns about patient privacy. Previously published computed tomography medical image sets 
with gross tumour volume (GtV) outlines for non-small cell lung cancer have been updated with 
extended follow-up. In a previous study, these were referred to as Lung1 (n = 421) and Lung2 (n = 221). 
The Lung1 dataset is made publicly accessible via The Cancer Imaging Archive (TCIA; https://www.
cancerimagingarchive.net). We performed a decentralized multi-centre study to develop a radiomic 
signature (hereafter “ZS2019”) in one institution and validated the performance in an independent 
institution, without the need for data exchange and compared this to an analysis where all data was 
centralized. The performance of ZS2019 for 2-year overall survival validated in distributed radiomics 
was not statistically different from the centralized validation (AUC 0.61 vs 0.61; p = 0.52). Although 
slightly different in terms of data and methods, no statistically significant difference in performance 
was observed between the new signature and previous work (c-index 0.58 vs 0.65; p = 0.37). Our 
objective was not the development of a new signature with the best performance, but to suggest an 
approach for distributed radiomics. Therefore, we used a similar method as an earlier study. We foresee 
that the Lung1 dataset can be further re-used for testing radiomic models and investigating feature 
reproducibility.
Introduction
Images from radiological examinations are presently one of the largest underutilized resources in healthcare “big 
data”1. Radiomics refers to computerized extraction of quantitative image metrics, known as “features”. In 2014, 
Aerts et al.2 showed that radiological features from Computed Tomography (CT) scans might encode additional 
information about phenotypic differences between tumours that lie beyond the grasp of the unaided human 
eye. The hypothesis is that multifactorial prediction models incorporating selected radiomic features may better 
inform individually personalized treatment strategies3–6. Radiomic data have now been investigated in CT7–9, 
magnetic resonance imaging (MRI)10,11 and positron emission tomography (PET)12,13.
The availability of commercial and open source software for radiomic feature extraction has made this line of 
inquiry accessible to a large number of investigators14–17. However, multi-institutional development and valida-
tion of radiomic-assisted prediction models is slowed down due to privacy concerns about sharing of individual 
patients’ medical images. Significant efforts are under way to make image sets used in radiomic investigations 
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openly accessible via centralized repositories such as The Cancer Imaging Archive (TCIA; https://www.cancerim-
agingarchive.net)18, however, many data owners remain cautious about sharing individual patient images publicly 
online.
A privacy-preserving distributed learning infrastructure based on World Wide Web Consortium “Semantic 
Web” data sharing standards19, known as Personal Health Train (PHT; https://vimeo.com/143245835)20 has been 
successfully used to develop and validate models on non-image clinical data21–23. To extend the PHT approach to 
radiomics, we first need to publish our radiomic features in a manner that is Findable, Accessible, Interoperable 
and Re-useable (FAIR)24. We have developed a pragmatic and extensible Radiomics Ontology (RO) that is pub-
licly accessible via NCBO BioPortal (https://bioportal.bioontology.org/ontologies/RO). With the RO, we can 
describe over 430 class objects and 60 predicates between objects to publish radiomic features (with some rela-
tionships and dependencies) according to Semantic Web standards. The class objects include unique feature iden-
tifiers that are aligned with the Image Biomarker Standardization Initiative (IBSI)25.
In this article, we show that the PHT infrastructure supports exchange of cross-institutional radiomic-based 
clinical data without material transfer of individual-level patient clinical data or images. Our primary objective 
was to show that external validation of a radiomic signature can be done with entirely decentralized data.
The specific use case was to learn a radiomic signature “ZS2019” for non-small cell lung cancer (NSCLC) 
overall survival at one institution and validate it at a remote institution in a distributed fashion. We included two 
of the NSCLC subject cohorts used by Aerts et al.2, however, with independently reviewed annotations (tumour 
delineations) and extended follow-up times for overall survival. We did not select new radiomic features, and 
instead used the four features corresponding to those described previously in the original publication, but using a 
different software implementation (see materials and methods). The first of these datasets (hereafter referred to as 
“Lung1”)26 was generated at Maastricht University, which was used exclusively for model training, thus obtaining 
coefficients for a four-feature signature in ZS2019. The second of these datasets (hereafter “Lung2”) was gener-
ated at Radboud University remains in a private hospital collection that could not be shared publicly for privacy 
reasons; Lung2 was used exclusively for model validation.
Results
Cohort summary information was exchanged through private discussion between the collaborating investiga-
tors, prior to performing this study. This was to confirm that general characteristics were comparable between 
the updated cohorts. This is shown in Table 1. None of the information contained in Table 1 was used in the 
model. There was a slightly higher proportion of patients with metastatic disease in Lung2 (10% vs 1%) compared 
to Lung1. The most common histology types in Lung1 were large-cell and squamous-cell carcinomas, whereas 
adenocarcinoma and squamous-cell carcinoma were most common in Lung2. The median follow-up time, the 
median survival time and the overall 2-year survival rate were similar in both cohorts.
We evaluated ZS2019 for 2-year overall survival using multivariable logistic regression. The area under the 
receiver operating characteristic curve (AUC) discrimination metric was 0.61 (95% confidence interval: 0.54 to 
0.69) in the Lung2 validation cohort.
Lung1
(n = 421)
Lung2
(n = 221)
Median age (range) at diagnosis in years 68.5 (34–92) 66.0 (36–87)
Median GTV size (range) in cm3 39 (0–660) 88 (1–860)
Clinical T stage
   Less than 3
   3 or greater
   Unknown
249 (59%)
171 (41%)
1 (0%)
119 (54%)
85 (38%)
17 (8%)
Clinical N stage
   0
   1
   2 or greater
   Unknown
170 (40%)
22 (5%)
229 (55%)
0 (0%)
49 (22%)
16 (7%)
137 (62%)
19 (9%)
Clinical M stage
   0
   1 or greater
416 (99%)
5 (1%)
200 (90%)
21 (10%)
Histology
   Adenocarcinoma
   Large-cell
   Squamous cell carcinoma
   Other, or not otherwise specified
   Unknown
51 (12%)
143 (34%)
152 (36%)
63 (15%)
12 (3%)
64 (29%)
22 (10%)
82 (37%)
47 (21%)
6 (3%)
Outcomes
   Median follow-up in days
   Median survival time in days
   2-year overall survival rate
546
478
40%
595
500
41%
Table 1. The clinical case-comparison for the training cohort (Lung1) and the validation cohort (Lung2). The 
abbreviations are: (GTV) is Gross Tumour Volume delineated on the radiotherapy treatment planning computed 
tomography image, (Clinical T) is the tumour staging, (Clinical N) is the node staging and (Clinical M) is the 
metastasis staging, respectively, according to the TNM tumour classification system.
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Distributed learning code for Cox regression in MATLAB (MATLAB 2016a, Mathworks, Natick MA, USA) 
was deployed via the PHT infrastructure connecting MAASTRO Clinic and Radboudumc. We retrieved anon-
ymous event timepoints and thus compiled Kaplan-Meier curves for overall survival in each of the training and 
validation cohorts (in Fig. 1). Within each cohort, the subjects were stratified into two risk groups, based on the 
median of the risk score distribution in Lung1. Stratification of survival curves by ZS2019 in the validation cohort 
was quantified via a Harrell Concordance Index (HCI) of 0.58, and a 95% confidence interval from 0.51 to 0.65. 
The discrimination was statistically significantly different from random (p < 0.0001) based on a bootstrapped 
Wilcoxon estimation. We performed the same bootstrapped Wilcoxon estimation between the mean HCI of 
model ZS2019 (0.58) and the HCI previously published by Aerts et al. (0.65)2, and found no evidence of signifi-
cant divergence (p = 0.37).
We confirmed that the same ZS2019 result was obtained when trained centrally on Lung1 and validated in 
Lung2. The analysis is given in a Python v3.6 JuPyter notebook that is made publicly available (https://gitlab.com/
UM-CDS/distributedradiomics). The central data approach yielded a HCI of 0.58 with a 95% confidence interval 
estimated by bootstrap sampling to be 0.53 to 0.64.
Discussion
In this paper, a model (ZS2019) derived from radiomic features and overall survival locally within one institution 
was able to be exchanged interoperably with an external institution, without mandating any transfer of either 
images, feature values or clinical outcomes at the individual subject level. This is an essential and unique con-
tribution to radiomic investigations, because we hereby demonstrate the concept for carrying out multi-centre 
radiomic studies with fully decentralized data. The results obtained with decentralized data were the same as if all 
the data had been brought into the same location. However, the unique advantage of our approach is that no one 
party needs to risk breaking patient confidentiality by exposing the original data to another party. Each institu-
tional data owner retains complete control over their privacy-sensitive patient data, and decides what they wish 
to share for a collaborative project.
We foresee that public access to the updated Lung1 dataset, accessible together with open source radiomics 
software code, encourages re-use of the data for validating models, investigating radiomic feature generalizability 
and deep-learning for image analysis.
To learn effectively across institutions, it is essential that the investigation should be led by clinical experts. 
Our approach does not bypass the need for human experts to communicate extensively before commencing a 
study, in order to establish consensus on: (i) what is the clinical question to be addressed, (ii) relevant inclusion 
and exclusion criteria, (iii) which datasets are appropriate for answering the question and (iv) how to define the 
radiomic features and outcome concepts.
With respect to handling errors and discrepancies for a distributed radiomics study, it is essential that each 
data owner takes responsibility for curation and quality assurance of the data, such that it conforms to the agreed 
consensus. Where errors are detected, it is only the owners of the data that are able to review, contextualize and 
correct their own data.
Fig. 1 The performance of radiomic signature ZS2019 according to Kaplan-Meier survival analysis. The 
signature was developed in Lung1 (MAASTRO; black line) and then distributedly validated in Lung2 
(Radboudumc; red line). The upper and lower survival curves were split according to the median of the Cox 
regression linear predictor from the Lung1 data, and applied to both Lung1 and Lung2 data. The Harrell 
concordance index in the test cohort was 0.58, the log-rank test yielded a p-value of 0.09 and the Wilcoxon test 
gave p-value < 0.0001.
4Scientific Data |           (2019) 6:218  | https://doi.org/10.1038/s41597-019-0241-0
www.nature.com/scientificdatawww.nature.com/scientificdata/
 In this study, both sites used the same feature extraction software, PyRadiomics. We retained the step of 
attaching metadata to the features using the Radiomics Ontology so that, in future, sites might be able to use 
different software but can still understand each other because features having the same metadata labels from this 
ontology will be unambiguously defined as being semantically identical. Besides applying an ontology, this also 
requires the different Radiomics feature extraction software to use the (exact) same feature calculation method.
The approach of making data FAIR using semantic ontologies has the benefit of allowing each data owner to 
keep their own native language and annotation conventions in the original data. No syntactic harmonization of 
the data below the level of the FAIR station needs to be enforced, and no data code-books need to be exchanged. 
The only prerequisite here is that partnering institutions must follow their consensus agreement to label the 
comparable outcomes and equivalent radiomic features with the same unique identifier from the same domain 
ontology.
To develop ZS2019, we attempted to follow, as closely as possible, the approach adopted in the original publi-
cation. The HCI and AUC results we reported above were built using radiomic features that might not be optimal 
for the updated datasets, because we chose to use the four features with names corresponding to those described 
previously in the supplementary material of the prior study27. Development of an optimal radiomic signature for 
NSCLC overall survival would require a detailed re-examination of features and feature selection in the updated 
datasets, which is not the primary objective of the present study.
The PHT approach utilises existing data to answer key questions in personalised healthcare, preventive 
medicine and value-based healthcare. PHT is one of a number of innovative approaches (DataSHIELD28 and 
WebDISCO29) where the research question is coded as machine-learning algorithms sent to wherever data may 
reside, instead of centralising all of the data at one location. This is achieved by (i) creating FAIR data stations, (ii) 
creating “trains” containing the research question as a machine-learning algorithm and (iii) establishing “tracks” 
to regulate the trains and securely transmit them to data stations. The PHT is thus a “privacy-by-design” archi-
tecture, since it enables controlled access to heterogeneous data sources for clinical research. This respects data 
protection and personal privacy regulations, and requires active engagement of data owners in the process.
We used Semantic Web standards to make radiomic features and outcome data available as FAIR stations in 
keeping with our trains metaphor. This included locally storing radiomic features and outcome states in Resource 
Description Format (RDF), and allowing semantic interoperability using a combination of the Radiomics 
Ontology and Radiation Oncology Ontology. The benefit of Semantic Web is to make distributed learning possi-
ble even if the underlying implementation of data extraction and storage differs between sites. The RDF standard 
makes it unnecessary to first know the internal structural organization of a remote database in order to success-
fully execute a local data retrieval query. Furthermore, as the diversity and complexity of the data within the FAIR 
stations increases in the future, an RDF triple store approach is sufficiently flexible to describe arbitrarily complex 
concepts without the need to redesign the database.
 Use of the Varian Learning Portal (VLP; Varian Medical Systems, Palo Alto, USA) was of benefit for dis-
tributed radiomics, because the software had already implemented the essential technical overheads (logging, 
messaging and internet security) required for such distributed studies. This included underlying legal agree-
ments between the parties and Varian, that makes distributed radiomics more scalable since one does need to 
revisit these common aspects above for each project. The VLP system had no effect on the mathematical results 
of our study because it was purely a way for us to securely transmit learning algorithms and trained models. 
Alternatives to VLP such as DataSHIELD (http://www.datashield.ac.uk)28, WebDisco (https://omictools.com/
webdisco-tool)29 and ppDLI (https://distributedlearning.ai/blog) may also be used for distributed radiomics. The 
differences between the present study and the original study may be traced to: (i) the original Matlab code is 
commercial confidential and not available to the authors, so we used PyRadiomics developed by van Griethuysen 
et al.15 as a practical alternative and (ii) we tried our best to replicate the original method using the documented 
steps in the original manuscript, but we also improved the survival follow-up such that many right-censored 
events were now confirmed deaths.
Conclusion
This study demonstrates the proof of concept for multi-centre distributed radiomics investigation without 
exchanging individual-level data or medical images using the PHT infrastructure. The results showed that the 
proposed decentralized approach achieved the identical results as the fully centralized approach. Moreover, we 
performed a radiomics study where data was stored in the FAIR station at the institute rather than publishing as 
open-source. Finally, the work of this study may be used as the basis for other types of radiomics studies such as 
binary classification or regression, not only limiting to survival analysis.
Methods
Patients. Subjects in this replication study were from the same cohorts of non-small cell lung cancer (NSCLC) 
patients previously treated with (chemo-)radiotherapy at MAASTRO Clinic (MAASTRO) and Radboud 
University Medical Centre (Radboudumc). These were previously labelled by Aerts et al.2 as cohorts “Lung1” and 
“Lung2”, respectively, and the same nomenclature is followed in this study. The Lung1 cohort (n = 421) was used 
only for fitting of model coefficients, and Lung2 (n = 221) was exclusively used for external validation.
Tumour delineations. Radiotherapy treatment planning DICOM CT images and physician-delineated pri-
mary NSCLC tumours as RT structure sets were used. From 422 available, 34 cases were found to have a reference 
frame translation between the image and delineation due to incorrect coding of the treatment couch height offset 
in the planning system; these have been rectified for the TCIA collection. Only 1 patient was post-operative radi-
otherapy, so this case was excluded from any further analysis, leading to 421 eligible cases in Lung1 for model 
training.
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In the Lung2 cohort, there were initially 267 subjects available. A check against delineation criteria found 221 
eligible primary tumours for radiomic analysis. The other 46 patients had either gross tumour volumes including 
lymph nodes, or were cases with neoadjuvant treatment or had no primary tumour in the list of structures.
Outcomes. Updated follow-up intervals in early 2018 with recent dates of death were obtained with ethics 
board permission from the Dutch citizens registry. As expected, the number of registered deaths in Lung1 and 
Lung2 had increased significantly since the original publication. The time intervals from date of first radiotherapy 
fraction to date of either registered death or last known survival were updated in both Lung1 and Lung2.
Data processing. The study steps are shown schematically in Fig. 2 for MAASTRO and Radboudumc. The 
core of the radiomic feature extraction process utilizes free and open-source PyRadiomics15 (v1.3) libraries. 
Software wrapper extensions collectively known as O-RAW (https://gitlab.com/UM-CDS/o-raw) were used to 
convert DICOM objects into numerical arrays as inputs for PyRadiomics; these were based on the SimpleITK 
(v1.0.1)30 toolkit.
The original MATLAB scripts used by Aerts et al. were not accessible to the current authors. The open source 
PyRadiomics was developed independently of this MATLAB code, and was based on the original study from 
Aerts et al. The PyRadiomics community has documented and standardized the feature calculation formulae 
(https://pyradiomics.readthedocs.io).
The image pre-processing methodology was the same as in the original publication2; an extraction intensity 
bin width was set at 25 Hounsfield Units with no image resampling and no image intensity normalization. The 
coif1 wavelet package from the pywavelets library (v0.5.2, https://github.com/PyWavelets/pywt) was used to gen-
erate wavelet features with a starting bin edge of 0. All of these settings are the default in PyRadiomics.
For the development of ZS2019 we did not select new radiomic features, and instead used the four features 
with names corresponding to those described previously in the supplementary material27 that accompanied the 
original publication:
 i. Energy from the intensity histogram feature class, which estimates the overall density of the region of 
interest,
 ii. Compactness from the morphological feature class, which describes the volume of the object relative to 
that of a perfect sphere,
 iii. Grey level run-length matrix (GLRLM) non-uniformity from the textural feature class, which is a measure 
of intensity heterogeneity averaged over 13 different directions in a 3D matrix of values, and
 iv. Wavelet-filtered (HLH) GLRLM non-uniformity, which was the same as (iii) after applying a wavelet 
decomposition filter over the original image.
In our work, the feature “compactness” had been deprecated in PyRadiomics, so we derived the mathemat-
ical equivalent of compactness by taking the cube of the shape feature “sphericity” (see formulae in Table A of 
Supplementary Materials).
Semantic web ontologies. Semantic Web technologies and ontologies play a key role in distributed learn-
ing by enabling semantic interoperability between data from multi-centres. In this study, radiomic features and 
clinical data were defined by a Radiomics Ontology v1.3 (https://bioportal.bioontology.org/ontologies/RO) and 
a Radiation Oncology Ontology31, respectively.
We elected to use the published open access Radiomics Ontology, that identifies radiomic features via a globally 
persistent unique identifier and allows us to attach important dependencies, such as digital image pre-processing 
steps, directly to each given feature. Though radiomic features definitions have been defined by previous investiga-
tors, our contention is that human-readable labels alone may not always be easily extensible to define dependencies 
such as software versions, image pre-processing steps and mathematical implementation of the feature. For exam-
ple, to avoid conflation between features labelled “entropy”, the IBSI distinguishes between Intensity Histogram 
Entropy (unique ID = TLU2) and the textural feature Joint Entropy (unique ID = TU9B). The Radiomic Ontology 
allows extensible and adaptable declaration of radiomic feature provenance by publishing it as a data graph object. 
Therefore, independent researchers (in the aforementioned example) who have computed Joint Entropy may use 
Fig. 2 A schematic diagram explaining the primary methodology for survival analysis used in this study. 
Details have been provided in the text. Briefly, radiomics features were extracted locally by each institution and 
then labelled with the radiomics ontology. We then trained a Cox regression model on Lung1 (MAASTRO) and 
then validated on Lung2 (Radboudumc) by distributing the learning algorithm through the Varian Learning 
Portal (VLP). Only the event coordinates required to plot a Kaplan-Meier survival curve was returned to 
MAASTRO, without any identifiable patient-level data.
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the SPARQL federated query language (https://www.w3.org/TR/rdf-sparql-query) on feature graphs to also probe 
for similarities in imaging setting, pre-processing methods, and suchlike. We hypothesise that the data graph based 
approach is more scalable than pairwise cross-referencing of multiple dictionaries of feature definitions.
Distributed approach. The VLP distributed learning architecture has been described in deep detail else-
where21–23. In brief, VLP consists of (i) a global web-based clinical learning environment that spans across any num-
ber of participating institutes for a given learning project, and (ii) a local connector application that runs exclusively 
inside the IT firewall of each institute. The former coordinates access permission, asynchronous messaging, web 
security and site privacy protocols across the learning network, while the latter hosts a local FAIR data repository. 
Radiomic feature values were hosted in the respective VLP local connector application (v2.0.1) as RDF.
Authenticated and verified (e.g. encrypted digital signature) machine learning packages are distributed via the 
global part of VLP, then picked up and executed on the RDF data via the local connector part. Only the statistical 
summary result of the computation, not any identifiable patient data, is thereafter passed back to the instigator 
via the global VLP part. Any process that had executed within local firewalls remain permanently quarantined 
from the global part.
Model training. The Lung1 radiomic feature values were log-transformed and then scaled to z-scores. A 
multivariable Cox proportional hazards model for overall survival (with removal of right censored subjects not 
yet deceased) was then fitted using all of the available subjects in the training cohort. The median risk score in the 
training cohort was recorded and thus used to stratify the training population into two risk groups. The fitted Cox 
model coefficients, the median risk score and the z-score transformations from the training cohort were packaged 
as self-contained validation application, which was then transmitted via VLP to Radboudumc.
At Radboudumc, the application queried the local RDF repository for the radiomic features, then applied 
the same log-transform of raw feature values and the same z-score scaling as had been executed on Lung1. For 
each available validation subject in Lung2, the risk score was computed and stratified according to the median 
risk score of Lung1. A flat table of individual timepoints and death/censor events was sent back via VLP to 
MAASTRO.
Cox model evaluation. Anonymous timepoints for Kaplan-Meier survival curves32 were retrieved over the 
PHT infrastructure. Risk scores were stratified into two strata according to the median value in the Lung1 popula-
tion. A Harrell concordance index (HCI)33 implemented using the python lifelines package (v0.14.4) was used to 
quantify discrimination performance using the retrieved timepoints. The log-rank method34 was used to calculate 
a chi-squared test statistic and p-value for the significance of the discrimination. To assess if the survival model 
had any value beyond random discrimination (null hypothesis: c-index = 0.5), we used a two-sided Wilcoxon test 
with a bootstrap approach on 100 repeated sub-samples of 100 patients per repetition from Lung2.
2-year overall survival. A multivariable logistic regression model for 2-year overall survival was devel-
oped on Lung1 then validated on Lung2 using the aforementioned four features. The area under the curve of the 
receiver operating characteristic was used to assess the discrimination. The bootstrap method (1000 times) was 
used to estimate a 95% confidence interval around the mean AUC.
Data availability
The Lung1 images, primary tumour delineations (from Method: tumour delineations) and clinical outcomes with 
updated follow-up (from Method: outcomes) has been approved for open access publication, and is curated as 
the collection called “NSCLC-Radiomics” via The Cancer Imaging Archive (TCIA)26. The clinical data for Lung1 
that support the findings of this study are also available in TCIA with the data identifier (https://doi.org/10.7937/
K9/TCIA.2015.PF0M9REI). Further information regarding the Lung1 data may be obtained from the authors 
responsible, A Dekker (email: andre.dekker@maastro.nl; address: Doctor Tanslaan 12, 6229 ET; Maastricht, The 
Netherlands; phone: +31 88 445 5600) and L Wee (email: leonard.wee@maastro.nl; address: Doctor Tanslaan 12, 
6229 ET; Maastricht, The Netherlands; phone: +31 88 445 5600).
The Lung2 dataset that support the findings of this study are available by request from the authors R 
Monshouwer (email: rene.monshouwer@radboudumc.nl; address: Radboud university medical center, 
Department of Radiation Oncology, Geert Grooteplein 32, 6525 GA, Nijmegen, The Netherlands; phone: +31 
24 361 4515) and J Bussink (email: jan.bussink@radboudumc.nl; address: Radboud university medical center, 
Department of Radiation Oncology, Geert Grooteplein 32, 6525 GA, Nijmegen, The Netherlands; phone: +31 24 
361 4515). This part of data are not publicly available due to the data containing information that could compro-
mise research participant privacy.
Code availability
The code used in this study is made publicly available on the Maastricht University Clinical Data Science (UM-
CDS) GitLab repository (https://gitlab.com/UM-CDS/distributedradiomics). The code repository has the 
following organization:
a.  D2RQ folder: contains the raw feature value to RDF mapping (D2RQ) script and the SPARQL query used 
to retrieve the local data into the local VLP connector application.
b.  VLP folder: contains the MATLAB codes submitted by the user into VLP, which then transmits it to the 
participating site for model validation and analysis.
c.  Analysis Centralized Learning folder: contains the Jupyter notebook from Radboudumc for model devel-
opment and evaluation on the aggregated datasets.
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The open-access Radiomics Ontology (RO) is published via the National Center for Biomedical Ontology 
(NCBO) ontology registry. It is available to download in a range of formats from the following URL: https://
bioportal.bioontology.org/ontologies/RO. As a domain ontology, the RO defines histogram-based, morpholo-
gy-based and texture-based radiomic features, including (since v.1.6, 08 November 2018) all feature entities pre-
sented in the International Biomarker Standardization Initiative. The ontology also defines software properties, 
digital imaging filter operations and feature extraction settings, together with relational predicates to link these 
to each feature entity.
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